Verrica Pharma reports wider-than-expected Q2 adj loss per share

Verrica Pharmaceuticals

06/08/2026 21:29

Overview
US dermatology therapeutics firm's Q2 revenue declined yr/yr as prior-year included one-time milestone
Adjusted loss per share for Q2 missed analyst expectations
Company reported record demand for YCANTH and secured $27.5 mln credit facility to extend cash runway

Outlook
Company expects topline data from Phase 3 common warts program in mid-2027
Verrica says cash runway could extend into 2028 with full access to new credit facility
Company continues patient enrollment in pivotal studies for YCANTH and VP-315

Result Drivers
YCANTH DEMAND - Co said record demand for YCANTH drove higher product revenue, with dispensed applicator units up 28% sequentially and 46% yr/yr
DISTRIBUTION PARTNER DELIVERIES - Co attributed increase in U.S. YCANTH product revenue primarily to increased deliveries to distribution partners
HIGHER OPERATING EXPENSES - Co said selling, general and administrative expenses rose due to increased commercial spend and sales force expansion, while R&D costs increased from Phase 3 program for common warts

Company press release: ID:nGNX7rLFKr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
Miss
$0.48
$0.38 (3 Analysts)
Q2 Adjusted Net Loss
 
$10.20 mln
 
Q2 Net Loss
 
$13.15 mln
 
Q2 Income from Operations 
 
-$13.10 mln
 

Reuters Recommended Reads
Aug 5 - Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Aug 6 - Aclaris Therapeutics Q2 revenue beats analyst estimates
Aug 6 - Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)